Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
In plain words A Phase 4 study of magnesium oxide in people 16 and older, run by Scarborough General Hospital. It plans to enroll about 3,853 people at 6 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 16 and older. Conditions: Critical Illness.
- Age 16 years or older
- Admission orders written to a medical-surgical intensive care unit at a participating site
- Magnesium replacement protocol ordered
The exclusion criteria are on the listing.
What it tests, as registered
Magnesium sulfate administration; Magnesium oxide; Magnesium glucoheptonate
Registered summary
In patients with critical illness, such as severe infections, heart attacks, or respiratory failure, most intensive care units (ICUs) measure magnesium levels and give supplemental doses of magnesium when levels are below certain targets. However, the best targets are unknown. The goal of this clinical trial is to study protocols for magnesium supplementation in people with critical illness, comparing a protocol with higher target level to a protocol with a lower target level. The full summary is on the listing.
Where, as registered
No US site; Canada (6).